Persistent abdominal pain, vomiting, and anorexia can signal valproate-associated pancreatitis, while anorexia, vomiting, weakness, or jaundice can indicate hepatotoxicity. Both complications can be life-threatening and require prompt evaluation. Mild transient gastrointestinal upset, brief dose-related drowsiness, and gradual hair thinning require routine monitoring but do not carry the same immediate pancreatitis or liver-failure concern.
Clinical reasoning Valproate has boxed and serious warnings for hepatotoxicity and pancreatitis. Their early symptoms can overlap, especially abdominal pain, nausea, vomiting, and loss of appetite.
Decision rule Escalate persistent abdominal symptoms or jaundice promptly and anticipate liver and pancreatic evaluation rather than treating them as routine adverse effects.
Scenario 31-year-old female with bipolar disorder starting valproic acid 500 mg PO BID. Receiving outpatient teaching about red-flag adverse effects.
Valproate hepatotoxicity — Potentially fatal liver injury that can begin with malaise, weakness, anorexia, vomiting, facial edema, or jaundice.
Valproate-associated pancreatitis — Potentially life-threatening pancreatic inflammation that can cause persistent abdominal pain, nausea, vomiting, and anorexia.
Hyperammonemia — Elevated blood ammonia from valproate inhibition of urea cycle; can cause encephalopathy even with normal LFTs.